![Lawrence Kenyon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lawrence Kenyon
Keine laufenden Positionen mehr
Vermögen: 67 703 $ am 31.08.2026
Profil
Lawrence A. Kenyon served as Chief Financial Officer, Secretary & EVP at NeoPharm, Inc. from 2000 to 2006.
Served as Director at Tamir Biotechnology, Inc. in 2009.
Served as Chief Financial Officer at Par Pharmaceutical, Inc. from 2009 to 2010.
Served as Chief Financial Officer & Executive Vice President at Endo Generics Holdings, Inc. from 2009 to 2010.
Served as President, CEO, CFO & Secretary at Tamir Biotechnology, Inc. in 2013.
Served as Chief Operating & Financial Officer at Arno Therapeutics, Inc. from 2014 to 2015.
Served as CEO, CFO, Secretary, Treasurer & Director at Outlook Therapeutics, Inc. from 2024 to 2025.
Attended the University of Wisconsin, completing undergraduate studies in 1987.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 14.08.2026 | 106’956 ( 0.07% ) | 67 703 $ | 31.08.2026 |
Ehemalige bekannte Positionen von Lawrence Kenyon
| Unternehmen | Position | Ende |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.07.2025 |
| ARNO THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.09.2015 |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Vorstandsvorsitzender | 31.03.2013 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Finanzdirektor/CFO | 01.07.2010 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Finanzdirektor/CFO | 04.06.2010 |
Ausbildung von Lawrence Kenyon
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
88
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Engages in discovering and developing new class of therapeutic drugs | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Operates as a holding company with interests in developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States | Health Technology |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology Provides drug research, development and commercialization services | Health Technology |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets generic drugs and pharmaceuticals products | Health Technology |
Arno Therapeutics, Inc.
 Arno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs | Health Technology |
Outlook Therapeutics, Inc.
 Outlook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures bevacizumab therapeutic products | Health Technology |
